Literature DB >> 11927016

The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil.

Muneyuki Masuda1, Satoshi Toh, Koji Koike, Yuichiro Kuratomi, Masumi Suzui, Atsuko Deguchi, Sohtaro Komiyama, I Bernard Weinstein.   

Abstract

We have used a combination of vitamin A (all-trans-retinyl palmitate), 5-fluorouracil (5-FU) and radiation to treat human head and neck squamous cell carcinoma (HNSCC). This chemoradiotherapy is called "FAR therapy." In this study we examined the effects of all-trans-retinoic acid (ATRA), the active metabolite of vitamin A, and ATRA plus 5-FU on two HNSCC cell lines (YCU-N861 and YCU-H891) to gain insight into the molecular mechanisms of FAR therapy. ATRA at 1 mM (the order of concentration found in HNSCC tumors treated with FAR therapy) inhibited cell proliferation and caused G1 cell cycle arrest in both cell lines. This was associated with a decrease in cyclin D1, an increase in p27(Kip1) and a reduction in the hyperphosphorylated form of retinoblastoma protein (pRB). With YCU-N861 cells, ATRA also caused a decrease in Bcl-2 and Bcl-X(L) and an increase in Bax. Both ATRA and 5-FU activated c-Jun N-terminal kinase (JNK) 1 and the combination of both agents resulted in additive or synergistic activation of JNK1, and also enhanced the induction of apoptosis. The YCU-H891 cells, in which the epidermal growth factor receptor (EGFR)-signal transducer and activator of transcription 3 (Stat3) pathway is constitutively activated, were more resistant to treatments with ATRA, 5-FU and the combination of both agents than YCU-N861 cells. A dominant negative Stat3 construct strongly enhanced the cellular sensitivity of this cell line to 5-FU but not to ATRA. In addition there is evidence that activation of Stat3 is associated with cellular resistance to radiation in HNSCC. Therefore, the addition to FAR therapy of agents that inhibit activation of the Stat3 pathway may enhance the clinical response of patients with HNSCC to FAR therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11927016      PMCID: PMC5926966          DOI: 10.1111/j.1349-7006.2002.tb02176.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


5‐fluorouracil all‐trans‐retinoic acid retinoic acid retinoic acid receptor head and neck squamous cell carcinoma cyclin‐dependent kinase retinoblastoma protein signal transducer and activator of transcription 3 c‐Jun N‐terminal kinase epidermal growth factor receptor transforming growth factor‐α phosphate‐buffered saline sodium dodecyl sulfate polyvinylidene difluoride hemaggultinin peptide sis‐inducible element
  58 in total

1.  Inhibited transformation of immortalized human bronchial epithelial cells by retinoic acid is linked to cyclin E down-regulation.

Authors:  J Langenfeld; F Lonardo; H Kiyokawa; T Passalaris; M J Ahn; V Rusch; E Dmitrovsky
Journal:  Oncogene       Date:  1996-11-07       Impact factor: 9.867

Review 2.  Epidermal growth factor receptor family and chemosensitization.

Authors:  J Mendelsohn; Z Fan
Journal:  J Natl Cancer Inst       Date:  1997-03-05       Impact factor: 13.506

3.  Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines.

Authors:  J I Song; M N Lango; J D Hwang; S D Drenning; Q Zeng; W W Lamph; J R Grandis
Journal:  Cancer Res       Date:  2001-08-01       Impact factor: 12.701

4.  Downregulation of JNK/SAPK activity is associated with the cross-resistance to P-glycoprotein-unrelated drugs in multidrug-resistant FM3A/M cells overexpressing P-glycoprotein.

Authors:  C D Kang; B K Ahn; C S Jeong; K W Kim; H J Lee; S D Yoo; B S Chung; S H Kim
Journal:  Exp Cell Res       Date:  2000-04-10       Impact factor: 3.905

5.  Enhancement of radiation effect on transformed fibroblastic cells by a synergistic combination of 5-fluorouracil and polyenes in vitro.

Authors:  S Komiyama; I Hiroto; M Kuwano; H Endo; K Koga
Journal:  Gan       Date:  1974-02

6.  Inhibition of stomal recurrence in laryngectomy with preoperative far therapy. A statistical evaluation.

Authors:  S Komiyama; H Watanabe; T Yanagita; M Kuwano; I Hiroto
Journal:  Auris Nasus Larynx       Date:  1984       Impact factor: 1.863

7.  Potentiation of cytostatic effect of sulfur- or chlorine-containing purines and related ribonucleosides by amphotericin-B on cultured mouse leukemia cells.

Authors:  M Kuwano; K Matsui; T Nakashima; H Endo; S Komiyama
Journal:  Gan       Date:  1975-12

8.  Isolation and characterization of an acute promyelocytic leukemia cell line selectively resistant to the novel antileukemic and apoptogenic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid.

Authors:  I Ponzanelli; M Giannì; R Giavazzi; A Garofalo; I Nicoletti; U Reichert; E Erba; A Rambaldi; M Terao; E Garattini
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

9.  1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death.

Authors:  Q Wang; W Yang; M S Uytingco; S Christakos; R Wieder
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

10.  all-trans retinoic acid enhances cisplatin-induced apoptosis in human ovarian adenocarcinoma and in squamous head and neck cancer cells.

Authors:  S Aebi; R Kröning; B Cenni; A Sharma; D Fink; G Los; R Weisman; S B Howell; R D Christen
Journal:  Clin Cancer Res       Date:  1997-11       Impact factor: 12.531

View more
  11 in total

1.  Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP.

Authors:  Mamta Gupta; Matthew J Maurer; Linda E Wellik; Mark E Law; Jing Jing Han; Nazan Ozsan; Ivana N Micallef; Ahmet Dogan; Thomas E Witzig
Journal:  Blood       Date:  2012-09-27       Impact factor: 22.113

Review 2.  Prioritization schema for immunotherapy clinical trials in glioblastoma.

Authors:  Tiffany R Hodges; Sherise D Ferguson; Hillary G Caruso; Gary Kohanbash; Shouhao Zhou; Timothy F Cloughesy; Mitchel S Berger; George H Poste; Mustafa Khasraw; Sujuan Ba; Tao Jiang; Tom Mikkelson; W K Alfred Yung; John F de Groot; Howard Fine; Lewis C Cantley; Ingo K Mellinghoff; Duane A Mitchell; Hideho Okada; Amy B Heimberger
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

Review 3.  Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art.

Authors:  Robert B Diasio; Jeanne Fourie
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Effect of all-trans retinoic acid on the growth of two nasopharyngeal cancer cell lines and its treatment potential in combination with cisplatin.

Authors:  Shih-Han Hung; Fei-Peng Lee; Chin-Hui Su; How Tseng
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-06-07       Impact factor: 2.503

5.  Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells.

Authors:  Ryuji Yasumatsu; Torahiko Nakashima; Muneyuki Masuda; Aya Ito; Yuichiro Kuratomi; Takashi Nakagawa; Shizuo Komune
Journal:  J Cancer Res Clin Oncol       Date:  2004-07-27       Impact factor: 4.553

Review 6.  Promising new molecular targeted therapies in head and neck cancer.

Authors:  Kelly Dorsey; Mark Agulnik
Journal:  Drugs       Date:  2013-03       Impact factor: 9.546

7.  Promising newer molecular-targeted therapies in head and neck cancer.

Authors:  Lili X Wang; Mark Agulnik
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 8.  Adaptive mechanisms of resistance to anti-neoplastic agents.

Authors:  Bibiana I Ferreira; Maria K Lie; Agnete S T Engelsen; Susana Machado; Wolfgang Link; James B Lorens
Journal:  Medchemcomm       Date:  2016-10-21       Impact factor: 3.597

Review 9.  Dietary Carotenoids in Head and Neck Cancer-Molecular and Clinical Implications.

Authors:  Katarzyna Starska-Kowarska
Journal:  Nutrients       Date:  2022-01-26       Impact factor: 5.717

10.  STAT3 polymorphism and Helicobacter pylori CagA strains with higher number of EPIYA-C segments independently increase the risk of gastric cancer.

Authors:  Gifone A Rocha; Andreia M C Rocha; Adriana D Gomes; César Ll Faria; Fabrício F Melo; Sérgio A Batista; Viviane C Fernandes; Nathálie B F Almeida; Kádima N Teixeira; Kátia S Brito; Dulciene Maria Magalhães Queiroz
Journal:  BMC Cancer       Date:  2015-07-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.